Are the Days of Unfettered Pharmaceutical Pricing Gone?

Jack Bailey, President of GlaxoSmithKline Plc’s U.S. Pharmaceuticals, is working on bringing new drugs to market as efficiently as possible and says the days of unfettered pricing are done. Read more here. (Source: Cynthia Koons, Bloomberg Business, 2/11/16)

You might also be interested in:

PAI and BresMed Join Forces to Support Expanded Use of More… 07/22/2019
ICER Signs Multi-Year Deal to Use New Cloud-Based Analytic… 02/20/2020
Biomarkers and Companion diagnostics: Payer Insights 09/26/2019
The Future of Personalised Medicine: The Role of Simulation… 01/25/2020
Leveraging Technology to Reduce Costs in Clinical Trials 06/30/2019
Real World Evidence (RWE) Solutions Market by Component,… 02/05/2020
HealthEconomics.Com, Scientist.Com Announce HEOR, RWE Partnership 04/10/2020